NPI 1306476809: Open Payments
NPI 1306476809. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$232 in 13 payments from 8 companies in 2025. Trend: 2023 $1,548 · 2024 $1,944 · 2025 $232
Food & beverage: $232
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Collegium Pharmaceutical, Inc. | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $28 |
| Alkermes, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Biogen, Inc. | 1 | $15 |
| ABBVIE INC. | 1 | $14 |
Products named: CAPLYTA, REXULTI, Jornay PM, Qelbree, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, ZURZUVAE.
